血塞通注射液联合西药治疗重型颅脑外伤的临床观察

目的观察血塞通注射液(简称血塞通)治疗急性重型颅脑外伤的临床效果。方法按标准选取重型颅脑外伤患者87例，随机分成两组，对照组(43例)行常规治疗，治疗组(44例)在常规治疗的基础上加用血塞通治疗，治疗后1、2周分别测颅内压(ICP)和行格拉斯哥昏迷评分(GCS)，3个月后行格拉斯哥预后评分(GOS)，比较两组的疗效。结果治疗组ICP低于对照组，GCS高于对照组，GOS优于对照组，3项指标两组比较差异均有显著性(P<0．05)。结论血塞通对重型颅脑外伤患者具有明显的临床治疗效果。

Clinical Observation on Effect of Xuesaitong Injection as Auxiliary Treatment of Severe Craniocerebral Injury

To evaluate the effect of Xuesaitong injection (XSTI, a preparation of Panax Notoginseng) as auxilliary treatment of severe craniocerebral injury. Methods Eighty-seven patients with severe craniocerebral injury were selected and randomly divided into the treated group (n=44) and the control group (n=43), they were treated with conventional treatment, and XSTI was given additionally to the treated group. Intracranial pressure (ICP) and Glasgow coma score (GCS) of all patients were measured after 1 or 2-week treatment, and Glasgow outcome scale (GOS) of them was determined 3 months later. Then the therapeutic effect in the two groups were compared. Results After treatment, the ICP was lower, GCS higher and GOS better in the treated group than those in the control group significantly, all showing statistical significance (P<0.05). Conclusion XSTI has marked clinical therapeutic effect in treating patients with severe craniocerebral injury.